Top Markets
Coin of the day
Scilex Holding Company Scilex Holding Company

Scilex Holding Company

SCLX
Rang in Aktien #25637
Scilex Holding Company is a biopharmaceutical enterprise that specializes in... Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid for epidural administration, currently undergoing Phase III trials for lumbosacral radicular pain. Another candidate, SP-103, is progressing through Phase II trials for managing low back pain. Furthermore, SP-104, a novel, low-dose, delayed-release naltrexone hydrochloride formulation, has successfully concluded Phase I clinical testing for the treatment of fibromyalgia. Its corporate offices are situated in Palo Alto, California. Scilex Holding Company operates as a subsidiary of Sorrento Therapeutics, Inc.
Aktienkurs
$5.61
Zuletzt synchronisiert: 2026-08-20
Marktkapitalisierung
$47.65M
Veränderung (1 Tag)
-0.68%
Veränderung (1 Jahr)
-67.26%
Land
US
Handel Scilex Holding Company (SCLX)

Kategorie

Kursverlauf für Scilex Holding Company (SCLX)
Höchster Schlusskurs: $6.52 am 2026-08-01

Niedrigster Schlusskurs: $346.22 am 2021-03-01
Kursverlauf der Aktie von Scilex Holding Company von 2021 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2026 (TTM) -26.12%
2025 -11.79%
2024 -61.32%
2023 -63.10%
2022 -63.74%
2021 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
$1.25K 75.69%
US
$268.08 49.82%
US
$262.00 25.06%
US
$489.01 44.10%
CH
$149.16 73.28%
US